Pulmonary dysfunction in systemic lupus erythematosus and anti-phospholipid syndrome patients

Scandinavian Journal of Rheumatology

Volumn 36, Issue 4, 2007, Pages 285-290

  Paran, D ^a,b   Fireman, E ^a   Levartovsky, D ^a   Elkayam, O ^a   Kaufman, I ^a   Litinsky, I ^a   Caspi, D ^a   Koifman, B ^a   Keren, G ^a   Schwarz, Y ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CARBON MONOXIDE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EOSINOPHIL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPUTUM ANALYSIS; SPUTUM CYTODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGE OF ONSET; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PLETHYSMOGRAPHY; RESPIRATORY FUNCTION TESTS; SPUTUM; VITAL CAPACITY;

EID: 34548336820     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740601153816     Document Type: Article

References (21)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 2002:87-95.
2. Kao AH, Manzi S. How to manage patients with cardiopulmonary disease? Best Pract Res Clin Rheumatol 2002;16:211-27.
3. Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: a 5-yr prospective study. Rheumatology 2004;43:1039-44.
4. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
5. D'Cruz D, Khamashta M, Hughes G. Pulmonary manifestations of systemic lupus erythematosus. In Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 2002: 663-83.
6. Paran D, Fireman E, Elkayam O. Pulmonary disease in systemic lupus erythematosus and the antiphospholipid syndrome. Autoimmunity Rev 2004;3:70-5.
7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
8. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11.
9. ATS statements - Snowbird workshop on standardization of spirometry. Am Rev Respir Dis 1979;119:831-8.
10. Fireman E. Induced sputum: opening a new window to the lung. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:263-71.
11. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
12. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol 2000;2:373-6.
13. Duncan DB. T-tests and intervals for comparisons suggested by the data. Biometrics 1975;31:339-59.
14. Marai I, Zandman-Goddard G, Shoenfeld Y. The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 2004;33:365-72.
15. Silberstein SL, Barland P, Grayzel AI, Koerner SK. Pulmonary dysfunction in systemic lupus erythematosus: prevalence, classification and correlation with other organ involvement. J Rheumatol 1980;7:187-95.
16. Nakano M, Hasegawa H, Takada T, Ito S, Muramatsu Y, Satoh M, et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology 2002;7:45-9.
17. James DG, Rizzato G, Sharma OP. Bronchoalveolar lavage: a window of the lung. Sarcoidosis 1992;9:3-14.
18. Thornton SC, Robbins JM, Penny R, Breit SN. Fibroblast growth factors in connective tissue associated interstitial lung disease. Clin Exp Immunol 1992;90:447-52.
19. McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004;50:1226-32.
20. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Ugalde J, Aguirre C. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004;13:900-5.
21. Laskin CA, Clark CA, Spitzer KA. Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts? Rheum Dis Clin North Am 2005;2:255-72.